Collectively, our data suggest that IL7-Fc preferentially enhances the antitumor effect of CD8+ T cells only under lymphopenic conditions, which might be due to the temporal rescue of tolerant self-tumor Ag-specific CD8+ T cells from peripheral tolerance. The gene discussed is CD8A; the disease is neoplasm.